JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression

Journal of the College of Physicians and Surgeons Pakistan

Volumn 21, Issue 8, 2011, Pages 472-475

  Pahore, Zaen Al Abideen ^a   Shamsi, Tahir S ^a   Taj, Mehwesh ^a   Farzana, Tasneem ^a   Ansari, Saqib H ^a   Nadeem, Muhammad ^a   Ahmad, Masood ^a   Naz, Arshi ^a  

^a National Institute of Blood Disease and Bone Marrow Transplantation   (Pakistan)

Author keywords

BCR ABL translocation; Blast crisis; Chronic myeloid leukemia; JAK2V617F mutation; Philadelphia chromosome

Indexed keywords

BCR ABL PROTEIN; HEMOGLOBIN;

ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DEMOGRAPHY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; GENE TRANSLOCATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MALE; POLYMERASE CHAIN REACTION; PROGNOSIS; SPLEEN SIZE; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; BLAST CRISIS; CHILD; CONFIDENCE INTERVALS; DISEASE PROGRESSION; FEMALE; HEMOGLOBINS; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; PHILADELPHIA CHROMOSOME; PROGNOSIS; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; TIME FACTORS; YOUNG ADULT;

EID: 80051752022     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kralevics RS, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779-90.
2. Campiotti L, Appio L, Solbiati F, Ageno W, Venco A. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. Leuk Res 2009; 33:212-7.
3. Hussein K, Bock O, Theophile K, Seegers A, Arps H, Basten O, et al. Chronic myeloproliferative diseases with concurrent BCRABL junction and JAK2V617F mutation. Leukemia 2008; 22: 1059-62. Epub 2007 Nov 1.
4. Jallades L, Hayette S, Tigaud I, Johnston A, Coiffier B, Magaud JP, et al. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res 2008; 32:1608-10.
5. Bornhäuser M, Mohr B, Oelschlaegel U, Bornhäuser P, Jacki S, Ehninger G, et al. Concurrent JAK2(V617F) mutation and BCRABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 2007; 21:1824-6. Epub 2007 May 3.
6. Curtin NJ, Campbell PJ, Green AR. The Philadelphia translocation and pre-existing myeloproliferative disorders. Br J Haematol 2005; 128:734-6.
7. Krämer A, Reiter A, Kruth J, Erben P, Hochhaus A, Müller M, et al. JAK2-V617F mutation in a patient with Philadelphiachromosome-positive chronic myeloid leukemia. Lancet Oncol 2007; 8:658-60.
8. Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 2007; 21:1103-4. Epub 2007 Feb 15.
9. Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 2007; 109:4106-7.
10. Krämer A. JAK2-V617F and BCR-ABL-double Jeopardy? Leuk Res 2008; 32:1489-90. Epub 2008 Apr 24.
11. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
12. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-61.
13. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005; 434:1144-8.
14. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387-97.
15. Kako S, Kanda Y, Sato T, Goyama S, Noda N, Shoda E, et al. Early relapse of JAK2V617F-positive chronic neutrophilic leukemia with CNS infiltration after unrelated bone marrow transplantation. Am J Hematol 2007; 82:386-90.
16. Khwaja A. The Role of Janus Kinases in haemopoiesis and haematological malignancy. Br J Haematol 2006; 134:366-84. Epub 2006 Jul 5.
17. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic myelofibrosis. N Eng J Med 2007; 356:459-68.
18. Tefferi A. JAK2 mutation in polycythemia vera-molecular mechanisms and clinical application. N Eng J Med 2007; 356: 444-5.
19. Campbell PJ, Green AR. Mechanism of disease: the Myeloproliferative disorders. N Eng J Med 2006; 355:2452-66.
20. Cheung B, Radia D, Pantedelis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher hemoglobin and increased risk of thrombosis in essential thrombocythemia. Br J Haematol 2005; 132:244-5.
21. Speletas M, Katodritou E, Daiou C, Mandala E, Papadakis E, Kioumi A, et al. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leuk Res 2007; 31:1053-62. Epub 2006 Oct 12.